Sangamo gets FDA nod for rolling BLA submission of Fabry disease therapy Nov 21, 2025 08:05AM
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease Nov 21, 2025 08:05AM
Sangamo presents data on Fabry disease gene therapy ahead of FDA filing Sep 4, 2025 08:05AM
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 Sep 4, 2025 08:05AM
Sangamo Therapeutics (SGMO) Announces Capsid License Agreement With Lilly (LLY) to Deliver Genomic Medicines for Diseases of the Central Nervous System Apr 3, 2025 04:01PM
View Older Stories

Apr 3, 2025 04:01PM Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Dec 19, 2024 02:30AM Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Dec 19, 2024 02:30AM Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Aug 6, 2024 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
Aug 6, 2024 08:07AM Sangamo Therapeutics (SGMO) Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
Aug 6, 2024 08:05AM Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
Jul 30, 2024 04:15PM Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Jul 24, 2024 06:57AM Sangamo Therapeutics (SGMO) Reports on Pfizer’s (PFE) Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
Jul 24, 2024 06:55AM Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
May 9, 2024 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 9, 2024 08:05AM Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 2, 2024 04:15PM Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Apr 22, 2024 04:35PM Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society
Mar 13, 2024 08:05AM Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Mar 13, 2024 08:01AM Sangamo Therapeutics (SGMO) Announces Data From AAV Capsid
Mar 13, 2024 08:01AM Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Mar 12, 2024 06:30PM Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Feb 12, 2024 08:05AM Sangamo Therapeutics (SGMO) Announces FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920
Feb 12, 2024 08:05AM Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Feb 6, 2024 05:52AM Sangamo Therapeutics (SGMO) Announces Updated Phase 1/2 STAAR Study Data
Feb 5, 2024 06:01PM Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
Nov 1, 2023 04:01PM Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
Oct 25, 2023 04:15PM Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Oct 24, 2023 02:01AM Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therap
Sep 20, 2023 04:15PM Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
Aug 8, 2023 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Aug 1, 2023 04:15PM Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
Jul 20, 2023 08:05AM Sangamo (SGMO) and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Jul 20, 2023 08:05AM Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Jul 17, 2023 08:06AM Sangamo Therapeutics (SGMO) Announces Research Evaluation and Option Agreement With Subsidiary of Lilly (LLY) for Novel Engineered Capsids
Jul 17, 2023 08:05AM Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Jun 29, 2023 08:05AM Sangamo Therapeutics (SGMO) and Voyager Therapeutics (VYGR) Enter License Deal for Epigenetic Regulation Treatment of Prion
Jun 29, 2023 08:05AM Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
May 22, 2023 08:05AM Sangamo Therapeutics (SGMO) Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 22, 2023 08:05AM Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 16, 2023 08:01AM Sangamo Therapeutics (SGMO) Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 16, 2023 08:00AM Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 2, 2023 04:30PM Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Apr 27, 2023 05:17AM Sangamo Therapeutics (SGMO) Reports Q1, Provides Strategic Update
Apr 26, 2023 05:28PM Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
Apr 19, 2023 04:15PM Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Feb 22, 2023 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Feb 22, 2023 03:02PM Sangamo Therapeutics (SGMO) Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
Feb 22, 2023 03:01PM Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
Feb 21, 2023 09:01AM Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
Nov 3, 2022 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Oct 27, 2022 04:15PM Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Oct 12, 2022 04:17AM Sangamo Therapeutics (SGMO) Reports Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity
Oct 12, 2022 03:01AM Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
Aug 30, 2022 06:01AM Sangamo Therapeutics (SGMO) Reports Updated Preliminary Phase 1/2 Data in Fabry Disease
View Older Stories